Study of Telisotuzumab Adizutecan for ctDNA-Positive Colorectal Cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug, Telisotuzumab Adizutecan, given through a vein (infusion) alone or with standard treatments for people with colorectal cancer who have no visible tumors on scans but still have cancer DNA (ctDNA) in their blood after surgery and chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with colorectal cancer (adenocarcinoma).
- You have had surgery and at least 3 months of platinum-based chemotherapy after surgery (or before surgery for rectal cancer).
- You have no signs of cancer on CT scans of your chest, abdomen, and pelvis taken within the last 6 weeks.
- You have a positive ctDNA test (cancer DNA in blood) within the last year after finishing chemotherapy or after surgery.
- You did not receive a type of chemotherapy called topoisomerase inhibitors (like irinotecan) as part of your after-surgery treatment.
- You have a surgical tissue sample available for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a new drug called telisotuzumab adizutecan, given with bevacizumab, works better than the current standard treatment for colorectal cancer that has spread and stopped responding to previous chemotherapy. The goal is to see if this new combination helps patients live longer.
This Phase 1 study uses a blood test called ctDNA to decide whether and how to adjust treatment in people with colon cancer who still have a small amount of disease left after surgery. If your blood test remains positive, the trial aims to reduce recurrence risk by guiding treatment changes.
This trial is testing a new drug (zanzalintinib) alone or with pembrolizumab to see if it can stop cancer from coming back in people with colorectal cancer who have no visible cancer on scans but still have tumor DNA in their blood.
This trial tests two immunotherapy drugs, botensilimab and balstilimab, for people with colorectal cancer who have had surgery and chemotherapy but still have detectable cancer DNA in their blood. The goal is to see if these drugs can help clear the remaining cancer cells.
This trial tests whether treatment for colon cancer after surgery can be guided by a blood test that looks for leftover cancer signals (ctDNA). It may help some people choose stronger or different chemo based on whether ctDNA is found after surgery.
This trial tests a new drug combination for people with metastatic colorectal cancer. The study includes an experimental antibody-drug conjugate (telisotuzumab adizutecan) plus standard chemotherapy and targeted therapies, to see if it works better than current options.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.